Cristina Gallego-Fabrega, Gerard Temprano-Sagrera, Jara Cárcel-Márquez, Elena Muiño, Natalia Cullell, Miquel Lledós, Laia Llucià-Carol, Jesús M Martin-Campos, Tomás Sobrino, José Castillo, Mònica Millán, Lucía Muñoz-Narbona, Elena López-Cancio, Marc Ribó, Jose Alvarez-Sabin, Jordi Jiménez-Conde, Jaume Roquer, Silvia Tur, Victor Obach, Juan F Arenillas, Tomas Segura, Gemma Serrano-Heras, Joan Marti-Fabregas, Marimar Freijo-Guerrero, Francisco Moniche, Maria Del Mar Castellanos, Alanna C Morrison, Nicholas L Smith, Paul S de Vries, Israel Fernandez-Cadenas, Maria Sabater-Lleal
BACKGROUND: Thrombolytic recombinant tissue-plasminogen activator (r-tPA) treatment is the only pharmacological intervention available in the ischemic stroke acute phase. This treatment is associated with an increased risk of intracerebral hemorrhages, known as hemorrhagic transformations (HT), which worsen patient's prognosis. OBJECTIVES: To investigate the association between genetically-determined natural hemostatic factors' levels, with increased risk of HT after r-tPA treatment...
December 14, 2023: Journal of Thrombosis and Haemostasis: JTH